Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex announced its Q1 2021 results, reporting revenues of $633.9 million, a modest increase of 0.5% year-over-year. However, on a constant currency basis, revenues fell by 2.6%. The GAAP diluted EPS dropped 43.2% to $1.58, while adjusted diluted EPS rose by 5.5% to $2.87. The company raised its full-year revenue growth guidance but lowered its GAAP diluted EPS forecast. A restructuring plan is in place, expected to yield annual savings of $13 million to $16 million.
Teleflex (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 a.m. (ET). A live audio webcast and presentation slides will be accessible on the investor section of the Teleflex website.
Teleflex is dedicated to medical technologies that enhance health and quality of life, with a diverse portfolio in areas like vascular access and emergency medicine. More information can be found at teleflex.com.
Teleflex Incorporated (NYSE: TFX) will announce its first quarter 2021 financial results before the market opens on April 29, 2021. An investor conference call is scheduled for 8:00 a.m. (ET) on the same day, accessible via a live audio webcast. A replay will be available from 11:00 a.m. on April 29 until May 6, 2021. Teleflex provides medical technologies aimed at improving patient health, focusing on innovation in various medical fields.
Teleflex is set to participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 9:15 AM (ET). Jake Elguicze, Treasurer and Vice President of Investor Relations, will present at the event. Investors can access a live audio webcast and slides on the company's website. Teleflex specializes in medical technologies aimed at improving health outcomes across various fields, including vascular access and anesthesia. For additional details, visit www.teleflex.com.
Teleflex announced that over 250,000 patients worldwide have been treated with the UroLift® System, a minimally invasive procedure for benign prostatic hyperplasia (BPH). In the U.S., BPH affects more than 42 million men, with about 12 million receiving treatment. The UroLift System differs from traditional options by providing rapid recovery and maintaining sexual function. Recent data reveal improved patient experiences with lower catheterization rates and higher satisfaction levels. The UroLift System has become a standard of care in urology practices, underscoring its effectiveness.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2021. Shareholders on record as of March 5, 2021 will receive this dividend. Teleflex focuses on providing medical technologies aimed at improving health outcomes, with a diverse portfolio that includes vascular access, cardiology, anesthesia, and more. For further details about their offerings, visit teleflex.com.
Teleflex reported fourth quarter 2020 revenues of $711.2 million, a 4.4% increase year-over-year, with adjusted diluted EPS of $3.25, down 0.9%. Full-year revenues fell 2.2% to $2.537 billion, alongside a 27.6% drop in GAAP diluted EPS to $7.10. The company estimates the COVID-19 pandemic had a $61 million negative impact on fourth-quarter revenue and $281 million for the full year. Looking ahead, 2021 guidance projects 10-11.5% revenue growth and adjusted diluted EPS between $12.50 and $12.70.
Teleflex Incorporated (NYSE: TFX) announced the submission of a Biologics License Application (BLA) for its investigational freeze dried plasma (FDP) candidate to the FDA. This candidate, developed in collaboration with the U.S. Army Medical Materiel Development Activity, aims to enhance emergency medical responses to battlefield injuries. The application is eligible for priority review and accelerated approval, facilitating potential rapid availability. The FDP is not yet FDA-approved. The announcement underscores Teleflex's innovation focus in medical technologies.
Teleflex Incorporated (NYSE: TFX) will be represented by CEO Liam Kelly at the Barclays Global Healthcare Conference on March 9, 2021, at 10:55 am ET. A live audio webcast of the event will be accessible on the investor section of Teleflex's website, along with a presentation slide deck. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions in various medical fields, including vascular access and emergency medicine. For more information, visit www.teleflex.com.
Teleflex Incorporated (NYSE: TFX) has successfully completed patient enrollment ahead of schedule in its clinical study evaluating specialty catheters and coronary guidewires for Chronic Total Occlusion (CTO) percutaneous coronary interventions. The study enrolled 150 patients across 13 US sites, concluding three months early. CTOs affect nearly 20% of patients undergoing coronary angiography, often leading to severe ischemia and cardiac dysfunction. The study aims to assess device performance and safety, with expectations for results to inform clinical practices in CTO procedures.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
